Myeloid Therapeutics.
Bayanan da aka gabatar a AACR 2022 sun nuna cewa Myeloid ya tsara kuma ya haɓaka dandamali na hanyoyin warkewa biyu, ATAK ™ CAR masu karɓa da kuma shirye-shiryen vivo mRNA, don ƙaddamarwa da kunna ikon ƙwayoyin myeloid don kai hari kan kansa ta hanyar sake fasalin rigakafi. Kwayoyin Myeloid sune farkon mawaƙa na amsawar rigakafi kuma suna taruwa ta halitta a cikin ciwace-ciwacen ciwace-ciwacen daji, a wasu lokuta suna wakiltar kashi saba'in da biyar na ƙwayar ƙwayar cuta. Sabuntawar Myeloid na mRNA don sashin myeloid suna faɗaɗa tasirin waɗannan ƙwayoyin cuta a cikin gwaje-gwajen vivo.
Littafin labari na Myeloid na CARs, wanda aka sani da ATAK™ Receptors, yana haɗu da sanin ƙari tare da yankuna masu siginar rigakafi da yawa. Masana kimiyyar Myeloid sun bincika haɗaɗɗun sigina na rigakafi da yawa waɗanda ba a tantance su ba da kuma gano mafi kyawun hanyoyin sigina da yawa. Haɗin sanin ciwon daji yana ɗaure tare da waɗannan sabbin wuraren siginar siginar ciki na ciki yana ba da damar sel myeloid su sake tsara su tare da haɗaɗɗun siginar rigakafi waɗanda ba a gano su a baya ba, wanda ke haifar da kashe ƙwayar cuta da faɗaɗa martanin rigakafin ƙwayar cuta.
Littafin labari na Myeloid a cikin dandalin injiniya na vivo musamman yana hari da kunna sel myeloid don fitar da mafi girman rigakafin cutar kansa. Ta wannan hanyar, Myeloid yana nuna cewa isar da ƙwayoyin lipid-nanoparticles (LNPs) suna haifar da sakamako na mRNA a cikin zaɓin ɗauka da magana ta sel myeloid a cikin vivo, wanda ke haifar da kashe kumburi mai ƙarfi a cikin nau'ikan ciwon sanyi da yawa. Waɗannan bayanan suna nuna yuwuwar fasahar Myeloid don tsara sel kai tsaye a cikin vivo.
"A taron AACR na wannan shekara, mun yi farin cikin gabatar da gagarumin ci gaba a duk faɗin dandamalin mu wanda ke nuna ikon ƙwayoyin myeloid don tsara manyan martanin rigakafi ta hanyar shirye-shiryen mRNA da kuma ATAK™ CARs na gaba," in ji Bruce McCreedy, Ph. D., Babban Jami'in Kimiyya na Myeloid. "Wadannan bayanan suna goyan bayan shirye-shiryen mu na ƙaddamar da gwaje-gwaje na asibiti don kimanta aminci da ayyukan 'yan takarar samfuran magunguna da yawa a cikin shekara mai zuwa, faɗaɗa bututun mu na asibiti."
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- The data presented at AACR 2022 illustrate that Myeloid has designed and developed two novel therapeutic platforms, ATAK™ CAR receptors and in vivo mRNA programming, to target and activate the ability of myeloid cells to attack cancer by immune reprogramming.
- Through this approach, Myeloid demonstrates that delivery of lipid-nanoparticles (LNPs) encapsulating mRNA results in selective uptake and expression by myeloid cells in vivo, leading to potent tumor killing in multiple cold tumor models.
- The combination of cancer recognition binders with these novel intracellular signaling domains allows myeloid cells to be reprogrammed with previously unexplored combinations of immune signals, leading to tumor killing and broad systemic anti-tumor responses.
